Singapore, a nation celebrated for its remarkable longevity, faces a growing challenge: a significant portion of its aging population experiences a decade or more of diminished health prior to the end of life. In response to this pressing societal concern, researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), are spearheading an innovative line of inquiry, investigating whether the fundamental biological processes underpinning aging can be modulated to preempt or mitigate age-related ailments, including the devastating neurodegenerative condition, Alzheimer’s disease. This pioneering work delves into the potential of a naturally occurring molecule, calcium alpha-ketoglutarate (CaAKG), a well-studied metabolite intrinsically linked to promoting healthy aging, to reverse critical memory-related brain dysfunctions characteristic of Alzheimer’s.
The findings, meticulously detailed in the scientific journal Aging Cell, emerged from a comprehensive study orchestrated by Professor Brian K. Kennedy, a distinguished figure in the Department of Biochemistry and Chair of the Healthy Longevity Translational Research Programme (TRP) at NUS Medicine. Professor Kennedy’s team sought to ascertain CaAKG’s capacity to enhance synaptic plasticity within Alzheimer’s disease models, restore the intricate signaling pathways essential for memory formation and retrieval, shield neurons from premature degradation, and generally foster more robust cognitive aging trajectories. This research signals a paradigm shift in therapeutic philosophy, moving beyond the traditional approach of managing individual disease symptoms towards geroprotective strategies—interventions designed to directly address the underlying biological mechanisms of aging itself.
The implications of this research for Alzheimer’s disease treatment are profound, offering a new avenue for intervention. "Our discoveries highlight the considerable potential of compounds associated with longevity to address the complexities of Alzheimer’s disease," stated Professor Kennedy. He further elaborated that "the research suggests that safe, naturally occurring substances like CaAKG could, in the future, serve as valuable adjuncts to existing therapeutic strategies aimed at safeguarding the brain and decelerating the progression of memory loss." A key advantage, Professor Kennedy noted, lies in the fact that alpha-ketoglutarate (AKG) is an endogenous molecule, meaning it is already present within the human body. Targeting these inherent pathways could potentially lead to reduced risk profiles and broader accessibility for a wider patient demographic. Consequently, this discovery may herald a powerful new approach to delaying cognitive deterioration and promoting enduring brain health throughout the aging process.
The study provided compelling evidence that CaAKG significantly improves intercellular communication within brain models exhibiting Alzheimer’s pathology. Specifically, it demonstrated a restorative effect on weakened communication links between neurons, a phenomenon crucial for learning and memory. Furthermore, the research indicated that CaAKG helped to re-establish associative memory, one of the earliest cognitive faculties to be compromised by Alzheimer’s disease. Given that endogenous levels of AKG tend to diminish with advancing age, the repletion of this vital molecule presents a promising strategy for bolstering brain vitality over time and potentially reducing the susceptibility to neurodegenerative disorders.
To elucidate the precise mechanisms by which CaAKG exerts its beneficial effects on learning and brain health, the research group meticulously examined a fundamental neurological process known as long-term potentiation (LTP). LTP is critical for the strengthening of connections between neurons, a process indispensable for acquiring new information and consolidating long-term memories. In the context of Alzheimer’s disease, LTP is severely impaired. The researchers observed that the administration of CaAKG successfully restored this vital process to normal functional levels.
Beyond its effects on synaptic potentiation, CaAKG was found to stimulate autophagy, the brain’s intrinsic cellular "housekeeping" mechanism responsible for clearing out damaged proteins and maintaining neuronal health. The molecule appeared to operate through a previously unidentified molecular pathway, enhancing neuronal adaptability by modulating L-type calcium channels and calcium-permeable AMPA receptors. Crucially, this mechanism bypassed the NMDA receptors, which are frequently compromised by the accumulation of amyloid plaques, a hallmark of Alzheimer’s disease. This selective action is particularly significant, as it suggests a way to enhance neuronal function without exacerbating existing damage.
Moreover, the research confirmed that CaAKG effectively restored synaptic tagging and capture, a sophisticated and essential biological mechanism that enables the brain to consolidate the association between experiences and the formation of lasting memories. This finding is particularly significant, suggesting that the compound may not only bolster fundamental memory capabilities but also support the more complex cognitive functions, such as higher-level learning, which are typically affected early in the course of Alzheimer’s disease.
The overarching objective of this investigation was to explore the potential of a compound primarily recognized for its role in extending healthy lifespan to address the multifaceted challenges posed by Alzheimer’s disease. "Our goal was to determine whether a compound originally explored for extending healthy lifespan could be helpful for Alzheimer’s disease," stated Dr. Sheeja Navakkode, the lead author of the study and a research scientist at the Healthy Longevity TRP, NUS Medicine. She emphasized that "understanding the cellular mechanisms by which CaAKG improves synaptic plasticity provides critical insights into novel therapeutic strategies for preserving memory and mitigating the effects of brain aging." This research opens a new chapter in the fight against neurodegenerative diseases, offering hope through the targeted modulation of the aging process itself.
About the Author
